Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of Imlunestrant Formulations and Effects of Food and Omeprazole in Healthy Females
NCT07918859Phase 1Not yet recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2026
- Primary completion
- Aug 2027
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of imlunestrant in breast cancer (7 arms), sponsored by Eli Lilly and Company. Primary endpoints: Maximum Concentration and Area Under the Concentration Versus Time Curve. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
imlunestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07918859.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07918859.